NC // Decision Intelligence powered by Claim Forensics

Know when the record to defend a claim is still moving.

Evidence often stabilizes before institutions formally act. We identify the evidence patterns that materially change the read—so you can decide while the window is still open.

For market access, medical affairs, and launch teams: know when a disputed claim your team is defending has stabilized—and whether it is ready for institutional recognition. Delivered as a 1-page decision brief.

One Claim To Defend / Support
One Decision Formulary / Coverage
Window Status Open / Narrowing

01 // THE PROBLEM

Evidence stabilizes before you present.

Evidence stabilizes before the market catches up. By identifying specific stability signals, we identify when a claim is ready for formal recognition—and when the evidence record is still moving.

We show what holds, what is contested, and what evidence shifts would change the call.

When this matters:

  • Formulary expansion business cases
  • Payer re-engagement materials
  • Objection handler updates
  • HEOR value dossier support
  • Coverage policy defense

02 // THE OUTPUT

A defense brief your team can forward to market access.

Each brief answers: Can this claim still be challenged, and how much time do we have?

Window status (Open / Narrowing / Closing), what holds, what is under stress, what would reverse the read, and a suggested action envelope for your defense strategy.

1-Page Decision Brief For Market Access / HEOR
  • Window Status: Open / Narrowing / Closing
  • What Changed: Trajectory of evidence shifts
  • What Holds: Stable evidence supporting the read
  • What Is Under Stress: Contested evidence points
  • What Would Reverse: Reversal conditions
Trust Boundary

We measure the decision window. We do not predict payer decisions or guarantee coverage success.

Start

Have a claim you need to defend before a decision locks?

Send the claim, the decision date, and your position. We respond within one business day with fit, limits, and whether the window to act is still open.

Requests require a verified institutional email address and are subject to current measurement scope.

Today's Read finerenone-cardiorenal
Hardening
Signal 0.38 / Gate 0.65
Phase 1b pending review. Other lanes: dossier-build.

Visual Debug

Page:

Width: px

Theme: